In The Business of Health Gisele Wertheim Aymes Founder of The World of Longevity speaks to Matt Stang Chairman of Delic Holdings Incorporated. Delic is listed on the Canadian Stock Exchange and is a leader in the psychedelic industry educating the public on psychedelic wellness and investment.
After decades of demonization and criminalization psychedelic drugs may soon shake up mainstream psychiatry, an industry that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.
The World’s top Universities are racing to set up psychedelic research centers and investors are pouring millions of dollars into the industry as restrictions around the use of psychedelics are begin to loosen.
“Psychedelic drugs are a subset of hallucinogenic drugs whose primary effect is to trigger non ordinary states of consciousness (known as psychedelic experiences or “trips”) via serotonin 2A receptor agonism. This causes specific psychological, visual and auditory changes and often a substantially altered state of consciousness. The classical psychedelics, the psychedelics with the largest scientific and cultural influence are mescaline, LSD, psilocybin and DMT.” Wikipedia